☰

arjun muralidharan, B.Pharm (Hons.) - Publications

Affiliations: 
Pharmacology University of Queensland, Saint Lucia, Queensland, Australia 
Area:
Neuropathic pain
Tree Info Grants Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Khan N, Muralidharan A, Smith MT. Attenuation of the Infiltration of Angiotensin II Expressing CD3+ T-Cells and the Modulation of Nerve Growth Factor in Lumbar Dorsal Root Ganglia - A Possible Mechanism Underpinning Analgesia Produced by EMA300, An Angiotensin II Type 2 (AT2) Receptor Antagonist. Frontiers in Molecular Neuroscience. 10: 389. PMID 29200998 DOI: 10.3389/Fnmol.2017.00389  0.319
2017 Muralidharan A, Park TSW, Mackie JT, Gimenez LGS, Kuo A, Nicholson JR, Corradini L, Smith MT. Establishment and Characterization of a Novel Rat Model of Mechanical Low Back Pain Using Behavioral, Pharmacologic and Histologic Methods. Frontiers in Pharmacology. 8: 493. PMID 28798688 DOI: 10.3389/Fphar.2017.00493  0.313
2016 Muralidharan A, Kuo A, Jacob M, Lourdesamy JS, Carvalho LM, Nicholson JR, Corradini L, Smith MT. Comparison of Burrowing and Stimuli-Evoked Pain Behaviors as End-Points in Rat Models of Inflammatory Pain and Peripheral Neuropathic Pain. Frontiers in Behavioral Neuroscience. 10: 88. PMID 27242458 DOI: 10.3389/Fnbeh.2016.00088  0.367
2015 Smith MT, Muralidharan A. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain. Expert Opinion On Therapeutic Targets. 19: 25-35. PMID 25315162 DOI: 10.1517/14728222.2014.957673  0.354
2014 Muralidharan A, Wyse BD, Smith MT. Analgesic efficacy and mode of action of a selective small molecule angiotensin II type 2 receptor antagonist in a rat model of prostate cancer-induced bone pain. Pain Medicine (Malden, Mass.). 15: 93-110. PMID 24433468 DOI: 10.1111/Pme.12258  0.363
2013 Muralidharan A, Smith MT. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments. Inflammopharmacology. 21: 339-63. PMID 23918298 DOI: 10.1007/S10787-013-0183-7  0.349
2013 Smith MT, Woodruff TM, Wyse BD, Muralidharan A, Walther T. A small molecule angiotensin II type 2 receptor (ATâ‚‚R) antagonist produces analgesia in a rat model of neuropathic pain by inhibition of p38 mitogen-activated protein kinase (MAPK) and p44/p42 MAPK activation in the dorsal root ganglia. Pain Medicine (Malden, Mass.). 14: 1557-68. PMID 23742186 DOI: 10.1111/Pme.12157  0.346
2013 Muralidharan A, Wyse BD, Smith MT. Optimization and characterization of a rat model of prostate cancer-induced bone pain using behavioral, pharmacological, radiological, histological and immunohistochemical methods. Pharmacology, Biochemistry, and Behavior. 106: 33-46. PMID 23500189 DOI: 10.1016/J.Pbb.2013.02.020  0.363
2012 Smith MT, Muralidharan A. Pharmacogenetics of pain and analgesia. Clinical Genetics. 82: 321-30. PMID 22779698 DOI: 10.1111/J.1399-0004.2012.01936.X  0.351
2011 Muralidharan A, Smith MT. Pain, analgesia and genetics. The Journal of Pharmacy and Pharmacology. 63: 1387-400. PMID 21988420 DOI: 10.1111/J.2042-7158.2011.01340.X  0.336
Show low-probability matches.